Follicular lymphoma: life beyond the third line.

In The Lancet Haematology, Carla Casulo and colleagues1 report on the characteristics, treatment patterns, and outcomes of 441 patients with relapsed or refractory follicular lymphoma who had received three or more lines of systemic therapy. Their study combined retrospective and prospective data collected in a multicentre database of patients from eight academic centres in the USA, so it fairly reflects the management of this population in the real world (with the proviso that the real world in this setting means high-income countries), as opposed to data from clinical trials.